Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about ALI: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
ALI is a concept in neurodegeneration research. Key relationships include: implicated in, regulates, causes. Associated with SEPSIS. Connected to 146 entities in the SciDEX knowledge graph.
No AI portrait yet
Knowledge base pages for this entity
graph TD
ALI["ALI"]
S100A9["S100A9"] -->|"activates"| ALI
SEPSIS["SEPSIS"] -->|"causes"| ALI
CRH["CRH"] -->|"regulates"| ALI
MAP1B["MAP1B"] -->|"implicated in"| ALI
MAP2["MAP2"] -->|"implicated in"| ALI
MAP6["MAP6"] -->|"implicated in"| ALI
LIS1["LIS1"] -->|"implicated in"| ALI
DCX["DCX"] -->|"implicated in"| ALI
CD2AP["CD2AP"] -->|"implicated in"| ALI
HCN1["HCN1"] -->|"implicated in"| ALI| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| S100A9 | activates | protein | 0.72 |
| SEPSIS | causes | disease | 0.72 |
| CRH | regulates | protein | 0.64 |
| MMP9 | associated_with | protein | 0.60 |
| SF3B1 | implicated_in | gene | 0.50 |
| DNA | implicated_in | gene | 0.50 |
| VEGFA | implicated_in | gene | 0.50 |
| MAP6 | implicated_in | gene | 0.50 |
| MET | implicated_in | gene | 0.50 |
| MCL1 | implicated_in | gene | 0.50 |
| HCN1 | implicated_in | gene | 0.50 |
| SMARCA4 | implicated_in | gene | 0.50 |
| NAD | implicated_in | gene | 0.50 |
| LZTR1 | implicated_in | gene | 0.50 |
| MAP1B | implicated_in | gene | 0.50 |
| APOB | implicated_in | gene | 0.50 |
| TERT | implicated_in | gene | 0.50 |
| MAP2 | implicated_in | gene | 0.50 |
| CD40 | implicated_in | gene | 0.50 |
| LIS1 | implicated_in | gene | 0.50 |
| DCX | implicated_in | gene | 0.50 |
| CD2AP | implicated_in | gene | 0.50 |
| LDL | implicated_in | gene | 0.50 |
| SLC16A2 | implicated_in | gene | 0.50 |
| SLC16A1 | implicated_in | gene | 0.50 |
| NADH | implicated_in | gene | 0.50 |
| EFNB1 | implicated_in | gene | 0.50 |
| MCU | implicated_in | gene | 0.50 |
| LETM1 | implicated_in | gene | 0.50 |
| REL | implicated_in | gene | 0.50 |
| HSPG2 | implicated_in | gene | 0.50 |
| MDM4 | implicated_in | gene | 0.50 |
| TP53 | implicated_in | gene | 0.50 |
| ERK | implicated_in | gene | 0.50 |
| AKT | implicated_in | gene | 0.50 |
| SRC | implicated_in | gene | 0.50 |
| EPHB4 | implicated_in | gene | 0.50 |
| RASA1 | implicated_in | gene | 0.50 |
| EEF1A1 | implicated_in | gene | 0.50 |
| AQP4 | implicated_in | gene | 0.50 |
| TCR | implicated_in | gene | 0.50 |
| GBM | implicated_in | gene | 0.50 |
| C1QA | implicated_in | gene | 0.50 |
| C1QC | implicated_in | gene | 0.50 |
| C1Q | implicated_in | gene | 0.50 |
| SPI1 | implicated_in | gene | 0.50 |
| IDH1 | implicated_in | gene | 0.50 |
| UNC5B | implicated_in | gene | 0.50 |
| NTN1 | implicated_in | gene | 0.50 |
| IDH2 | implicated_in | gene | 0.50 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD | exploratory | Parkinson's disease | 0.900 | 0.00 | iPSC-derived dopaminergic neur | proposed | N/A |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| ApoE4 Function in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $360,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Metal Ion Homeostasis Dysregulation in Alzheimer's Disease | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] | Calvier L, Herz J, Hansmann G | JACC Basic Transl Sci | 2022 | 1 |
| ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] | Raulin AC, Doss SV, Trottier ZA, Ikezu T | Mol Neurodegener | 2022 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] | Brophy ML, Dong Y, Tao H, Yancey PG, Son | Circ Res | 2019 | 1 |
| Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] | Shinohara M, Tachibana M, Kanekiyo T, Bu | J Lipid Res | 2017 | 1 |
| Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of [PMID:41422555] | Mishra AK, Jain S | ACS Chem Neurosci | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| The association of Alzheimer's disease-related SNPs with mild cognitive impairme [PMID:41606232] | Xie Z, Tu W, Ye XF, Hua L, Zhang X et al | Sci Rep | 2026 | 0 |
| Genetic risk factors of late-onset Alzheimer's disease: Insights into pathophysi [PMID:41622452] | Akkaoui J, Devadoss D, Rodriguez MD, Ari | Neural Regen Res | 2026 | 0 |
| Genetic Burden and <i>APOE</i> Methylation in a Korean Multi-Generational Alzhei [PMID:41745359] | Eom Je-Hyun; Cho Mu-Yeol; Kim Ji-Won; Ki | Journal of personalized medici | 2026 | 0 |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, [PMID:41893052] | Burdman Gabriel; Akkaoui Juliet; Colon N | Neurology international | 2026 | 0 |
| Posttraumatic stress disorder is associated with Alzheimer's disease-relevant mo [PMID:41960318] | Seijo MA, Yohannes PA, Rogers AL, Gonzal | Res Sq | 2026 | 0 |
| Genetic risk factors of late-onset Alzheimer's disease: Insights into pathophysi [PMID:41622452] | Akkaoui J, Devadoss D, Rodriguez MD, Ari | Neural regeneration research | 2026 | 0 |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, [PMID:41893052] | ["Burdman G", "Akkaoui J", "Colon N", "P | Neurology international | 2026 | 0 |
| APOE-Targeted Therapeutics for Alzheimer's Disease. [PMID:41224653] | ["Yassine H", "Hugo C", "O'Donovan B", " | The Journal of neuroscience : | 2025 | 0 |
| Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker [PMID:39841474] | ["Oomens J", "van Gils V", "Vos S", "Fre | JAMA network open | 2025 | 0 |
| AMBP protects against aortic valve calcification by inhibiting ERK1/2 and JNK pa [PMID:40225558] | ["Guo C", "Liu X", "Mei Z", "Chang M", " | Theranostics | 2025 | 0 |
| Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab s [PMID:41085131] | ["Bauer A", "Rabe C", "Schiffman C", "Ro | Alzheimer's & dementia : the j | 2025 | 0 |
| ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetr [PMID:40987376] | Ge T, Niu A, Lv Y, Chen Y, Liu Y, Lei X, | Journal of controlled release | 2025 | 0 |
| Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alv [PMID:38671323] | ["Theobald H", "Bejarano D", "Katzmarski | Nature immunology | 2024 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning ALI in their description or question text
Score: 0.792 · neuroscience · 2026-04-07
## Mechanistic Overview Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling starts from the claim that mod
Score: 0.776 · neurodegeneration · 2026-04-16
## Mechanistic Overview CX3CR1-TREM2 Integration for Synapse Pruning Normalization starts from the claim that modulating
Score: 0.769 · unknown disease · 2026-04-12
## Mechanistic Overview Direct Toxicity Hypothesis: β-Amyloid Directly Impairs Cholinergic Signaling starts from the cla
Score: 0.718 · neurodegeneration · 2026-04-02
## Mechanistic Overview Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating
Score: 0.713 · neurodegeneration · 2026-04-02
## Mechanistic Overview Purinergic Signaling Polarization Control starts from the claim that modulating P2RY1 and P2RX7
Score: 0.710 · neuroscience · 2026-04-22
**Molecular Mechanism and Rationale** The molecular basis for selective liver X receptor beta (LXRβ/NR1H2) agonism in A
Score: 0.710 · neuroscience · 2026-04-26
FRAP-based measurement of TDP-43 liquid-liquid phase separation state provides a continuous biomarker of nuclear-cytopla
Score: 0.709 · neurodegeneration · 2026-04-02
## **Molecular Mechanism and Rationale** The lysyl oxidase (LOX) family comprises six enzymes—LOX, LOXL1, LOXL2, LOXL3,
Score: 0.708 · synaptic biology · 2026-04-21
## Mechanistic Overview TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Re
Score: 0.672 · neuroscience · 2026-04-12
## **Molecular Mechanism and Rationale** The astrocytic-mediated tau clearance dysfunction hypothesis centers on the pa
Score: 0.670 · neurodegeneration · 2026-04-25
Aβ drives tau into dendritic spines, where tau binds Fyn and stabilizes a PSD95-NMDAR-associated excitotoxic scaffold. O
Score: 0.670 · neurodegeneration · 2026-04-13
## Mechanistic Overview Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism starts from the claim that
Score: 0.669 · neurodegeneration · 2026-04-02
## Mechanistic Overview Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication start
Score: 0.660 · neuroinflammation · 2026-04-21
## Mechanistic Overview Chronic cGAS/STING Hyperactivation Drives Progressive Neurodegeneration Through Sustained Type I